Siegel, R. L. et al. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10 (2025).
Google Scholar
Bräutigam, K. et al. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited-exploring the “Space”. Cancer Lett. 622, 217699 (2025).
Google Scholar
Giurini, E. F., Ralph, O., Pappas, S. G. & Gupta, K. H. Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy. Mol. Can. Ther. 24, 18–32 (2025).
Google Scholar
Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056–2072 (2019).
Google Scholar
Kwon, J. Y., Vera, R. E. & Fernandez-Zapico, M. E. The multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer. Cell Signal. 127, 111584 (2025).
Google Scholar
Nagaraju, G. P. et al. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep. Med. 6, 101881 (2025).
Google Scholar
He, S., Zheng, L. & Qi, C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol. Cancer 24, 5 (2025).
Google Scholar
Bulle, A. et al. Gemcitabine recruits M2-type tumor-associated macrophages into the stroma of pancreatic cancer. Transl. Oncol. 13, 100743 (2020).
Google Scholar
Zhu, Y. H. et al. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Cell Oncol. 46, 17–48 (2023).
Google Scholar
Liudahl, S. M. et al. Leukocyte heterogeneity in pancreatic ductal adenocarcinoma: phenotypic and spatial features associated with clinical outcome. Cancer Discov. 11, 2014–2031 (2021).
Google Scholar
Finan, J. M., Guo, Y., Goodyear, S. M. & Brody, J. R. Challenges and opportunities in targeting the complex pancreatic tumor microenvironment. JCO Oncol. Adv. 1, e2400050 (2024).
Google Scholar
Luong, T., Golivi, Y., Nagaraju, G. P. & El-Rayes, B. F. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Cytokine Growth Factor Rev. 68, 107–115 (2022).
Google Scholar
Bachem, M. G. et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907–921 (2005).
Google Scholar
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
Google Scholar
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
Google Scholar
Carpenter, E. S. et al. Pancreatic Cancer–associated Fibroblasts: where do we go from here?. Cancer Res. 84, 3505–3508 (2024).
Google Scholar
Zhang, T. et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 13, 897 (2022).
Google Scholar
Ma, C. et al. Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment. Mol. Cancer 22, 170 (2023).
Google Scholar
Menezes, S. et al. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets. J. Pathol. 257, 526–544 (2022).
Google Scholar
Li, Y. et al. Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment. J. Transl. Med. 23, 697 (2025).
Google Scholar
Peng, D. et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol. Cancer 21, 104 (2022).
Google Scholar
Miyazawa, K., Itoh, Y., Fu, H. & Miyazono, K. Receptor-activated transcription factors and beyond: multiple modes of Smad2/3-dependent transmission of TGF-β signaling. J. Biol. Chem. 300, 107256 (2024).
Google Scholar
Giarratana, A. O., Prendergast, C. M., Salvatore, M. M. & Capaccione, K. M. TGF-β signaling: critical nexus of fibrogenesis and cancer. J. Transl. Med. 22, 594 (2024).
Google Scholar
Chan, M. K.-K. et al. Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy. Expl Target Antitumor Ther. 4, 316 (2023).
Google Scholar
Derynck, R., Turley, S. J. & Akhurst, R. J. TGFβ biology in cancer progression and immunotherapy. Nat. Rev. Clin. Oncol. 18, 9–34 (2021).
Google Scholar
Gumede, D. B., Abrahamse, H. & Houreld, N. N. Targeting Wnt/β-catenin signaling and its interplay with TGF-β and Notch signaling pathways for the treatment of chronic wounds. Cell Commun. Signal. 22, 244 (2024).
Google Scholar
Yang, N., Hellevik, T., Berzaghi, R. & Martinez-Zubiaurre, I. Radiation-induced effects on TGF-β and PDGF receptor signaling in cancer-associated fibroblasts. Cancer Rep. 7, e2018 (2024).
Google Scholar
Qin, Q. et al. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: challenges and opportunities. Cancer Lett. 591, 216859 (2024).
Google Scholar
D’Agosto, S. et al. Loss of FGFR4 promotes the malignant phenotype of PDAC. Oncogene 41, 4371–4384 (2022).
Google Scholar
Bordignon, P. et al. Dualism of FGF and TGF-β signaling in heterogeneous cancer-associated fibroblast activation with ETV1 as a critical determinant. Cell Rep. 28, 2358–2372.e2356 (2019).
Google Scholar
Tang, H. et al. Heterogeneity and function of cancer-associated fibroblasts in renal cell carcinoma. J. Nat. Can. Cen. 3, 100–105 (2023).
Khan, A. A. et al. An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression. Cancer Metastasis Rev. 40, 245–272 (2021).
Google Scholar
Hosein, A. N., Brekken, R. A. & Maitra, A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505 (2020).
Google Scholar
Xu, X. et al. Nanomedicine strategies to circumvent intratumor extracellular matrix barriers for cancer therapy. Adv. Health. Mater. 11, 2101428 (2022).
Google Scholar
Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int. J. Mol. Sci. 23, 146 (2021).
Google Scholar
Guo, T. & Xu, J. Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy. Cancer Metastasis Rev. 43, 1–22 (2024).
Google Scholar
Tape, C. J. et al. Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell 165, 910–920 (2016).
Google Scholar
Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637–646 (2013).
Google Scholar
Principe, D. R. et al. TGFβ signaling in the pancreatic tumor microenvironment promotes fibrosis and immune evasion to facilitate tumorigenesis. Cancer Res. 76, 2525–2539 (2016).
Google Scholar
Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525–530 (2015).
Google Scholar
Yang, D., Liu, J., Qian, H. & Zhuang, Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322–1332 (2023).
Google Scholar
Diab, M. & El-Rayes, B. F. The heterogeneity of CAFs and immune cell populations in the tumor microenvironment of pancreatic adenocarcinoma. J. Cancer Metastasis Treat. 8, 10.20517 (2022).
Google Scholar
Li, K.-Y. et al. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects. Chin. Med. J. Transl. Med. 6, 6–17 (2020).
Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131 (2021).
Google Scholar
Zhang, Z. et al. Heterogeneous cancer-associated fibroblasts: a new perspective for understanding immunosuppression in pancreatic cancer. Immunol 167, 1–14 (2022).
Google Scholar
Rebelo, R., Xavier, C. P., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol. Med. 29, 439–453 (2023).
Google Scholar
Mijit, M. et al. Role of p53 in the regulation of cellular senescence. Biomolecules 10, 420 (2020).
Google Scholar
Pandey, S. N. et al. ATM and p53 in aging and cancer: A double-edged sword in genomic integrity. Biogerontology 26, 102 (2025).
Google Scholar
Balaraman, A. K. et al. The interplay of p16INK4a and non-coding RNAs: bridging cellular senescence, aging, and cancer. Biogerontology 26, 50 (2025).
Google Scholar
Wang, T. Senescent Carcinoma Associated Fibroblasts Up-regulate Interleukin 8 to Enhance Pancreatic Cancer Progression. University of Toronto: Canada, 2015.
Bientinesi, E. et al. Doxorubicin-induced senescence in normal fibroblasts promotes in vitro tumour cell growth and invasiveness: the role of Quercetin in modulating these processes. Mech. Ageing Dev. 206, 111689 (2022).
Google Scholar
Cortesi, M. et al. Pancreatic cancer and cellular senescence: tumor microenvironment under the spotlight. Int. J. Mol. Sci. 23, 254 (2021).
Google Scholar
Rafaqat, S. et al. Role of interleukins in pancreatic cancer: a literature review. J. Gastrointest. Cancer 55, 1498–1510 (2024).
Google Scholar
Zhang, Z. & Zhang, H.-J. Glycometabolic rearrangements–aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential. Expert Opin. Ther. Targets 25, 1077–1093 (2021).
Google Scholar
Wang, Y. et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Disc. 7, 36 (2021).
Google Scholar
Melchionna, R. et al. Transcription factors in fibroblast plasticity and CAF heterogeneity. J. Exp. Clin. Cancer Res. 42, 347 (2023).
Google Scholar
Shakiba, M. & Tuveson, D. A. Macrophages and fibroblasts as regulators of the immune response in pancreatic cancer. Nat. Immunol. 25, 1–14 (2025).
Vaish, U., Jain, T., Are, A. C. & Dudeja, V. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma: an update on heterogeneity and therapeutic targeting. Int. J. Mol. Sci. 22, 13408 (2021).
Google Scholar
Koppensteiner, L., Mathieson, L., O’Connor, R. A. & Akram, A. R. Cancer associated fibroblasts-an impediment to effective anti-cancer T cell immunity. Front. Immunol. 13, 887380 (2022).
Google Scholar
Ren, F. et al. Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. J. Exp. Clin. Cancer Res. 44, 33 (2025).
Google Scholar
Song, J. et al. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat. Commun. 16, 2175 (2025).
Google Scholar
Maru, S. Y. et al. Antigen-presenting cancer-associated fibroblasts in murine pancreatic tumors differentially control regulatory T cell phenotype and function via CXCL9 and CCL22. Preprint at https://doi.org/10.1101/2025.03.27.645833 (2025).
Cole, K., Al-Kadhimi, Z. & Talmadge, J. E. Role of myeloid-derived suppressor cells in tumor recurrence. Cancer Metastasis Rev. 42, 113–142 (2023).
Google Scholar
Gautam, S. K., Batra, S. K. & Jain, M. Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma. Mol. Cancer 22, 118 (2023).
Google Scholar
Nakamura, K. & Smyth, M. J. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol. Immunol. 17, 1–12 (2020).
Google Scholar
Tamura, R. et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med. Oncol. 37, 1–14 (2020).
Google Scholar
Li, O. et al. Biological characteristics of pancreatic ductal adenocarcinoma: initiation to malignancy, intracellular to extracellular. Cancer Lett. 574, 216391 (2023).
Google Scholar
Zhu, T. et al. The role of innate immune cells as modulators of the tumor microenvironment in the metastasis and treatment of pancreatic cancer. Clin. Cancer Bull. 2, 2 (2023).
Google Scholar
Fyfe, J. et al. Immune evasion on the nanoscale: small extracellular vesicles in pancreatic ductal adenocarcinoma immunity. Semin Cancer Biol. 96, 36–47 (2023).
Google Scholar
Ohshio, Y., Hanaoka, J., Kontani, K. & Teramoto, K. Tranilast inhibits the function of cancer-associated fibroblasts responsible for the induction of immune suppressor cell types. Scand. J. Immunol. 80, 408–416 (2014).
Google Scholar
Kumar, V. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell. 32, 654–668. e655 (2017).
Google Scholar
Trovato, R. et al. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J. Immunother. Cancer 7, 255 (2019).
Google Scholar
Tong, X. et al. The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Theranostics 15, 2794–2813 (2025).
Google Scholar
Liu, R. et al. Tumor cells induce neural DKK1 expression to promote MDSC infiltration and subsequent T cell suppression. Cell Signal. 127, 111576 (2025).
Google Scholar
Rojas, L. A. & Balachandran, V. P. Scaling the immune incline in PDAC. Nat. Rev. Gastroenterol. Hepatol. 18, 453–454 (2021).
Google Scholar
Dahal, A. et al. Platelet-activating factor (PAF) promotes immunosuppressive neutrophil differentiation within tumors. Proc. Natl. Acad. Sci. USA 121, e2406748121 (2024).
Google Scholar
Liu, X. et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut 72, 2329–2343 (2023).
Google Scholar
Sun, R. et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Mol. Ther. 31, 3193–3209 (2023).
Google Scholar
Kajiwara, Y. et al. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Cancer Immunol. Immunother. 72, 1285–1300 (2023).
Google Scholar
Neander, C. Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma. Universität Duisburg-Essen: Duisburg, Essen, 2020). Dissertation.
Pan, Y., Yu, Y., Wang, X. & Zhang, T. Tumor-associated macrophages in tumor immunity. Front. Immunol. 11, 583084 (2020).
Google Scholar
Mazzone, M., Menga, A. & Castegna, A. Metabolism and TAM functions—it takes two to tango. FEBS J. 285, 700–716 (2018).
Google Scholar
Magri, S. et al. The immunosuppression pathway of tumor-associated macrophages is controlled by heme oxygenase-1 in glioblastoma patients. Int. J. Cancer 151, 2265–2277 (2022).
Google Scholar
Zhang, H. et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol. Cancer 22, 1–23 (2023).
Google Scholar
Mingari, M. C. et al. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol. 61, 44–50 (2000).
Google Scholar
Zhou, Y., Cheng, L., Liu, L. & Li, X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol. Cancer 22, 34 (2023).
Google Scholar
Caronni, N. et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415–422 (2023).
Google Scholar
Tabe, S. et al. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Biomaterials 314, 122838 (2025).
Google Scholar
Zhong, Z. et al. Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. Cancer Lett. 588, 216784 (2024).
Google Scholar
Xu, H. et al. CREB3L1 facilitates pancreatic tumor progression and reprograms intratumoral tumor-associated macrophages to shape an immunotherapy-resistance microenvironment. J. Immunother. Cancer 13, e010029 (2025).
Google Scholar
Chen, Y. et al. Macrophage-derived exosomal microRNAs promote metastasis in pancreatic ductal adenocarcinoma. Int. Immunopharmacol. 129, 111590 (2024).
Google Scholar
Chakkera, M., Foote, J. B., Farran, B. & Nagaraju, G. P. Breaking the stromal barrier in pancreatic cancer: advances and challenges. Biochim. Biophys. Acta Rev. Cancer 1879, 189065 (2024).
Google Scholar
Wu, Y. et al. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).
Google Scholar
Sawant, A. et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 73, 672–682 (2013).
Google Scholar
Liu, R. et al. Tumor-associated macrophages (TAMs): constructing an immunosuppressive microenvironment bridge for pancreatic ductal adenocarcinoma (PDAC)☆. Cancer Pathog. Ther. 3, 183–196 (2025).
Google Scholar
Wang, S. et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis. Oncol. 8, 31 (2024).
Google Scholar
Li, A.-Q. et al. Understanding the complexity of tumor-associated macrophages: druggable and therapeutic insights. Acta Pharm. Sin. B. 15, 4456–4475 (2025).
Google Scholar
Hussain, Z. et al. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Cell Commun. Signal. 22, 1 (2024).
Google Scholar
Halbrook, C. J., Lyssiotis, C. A., di Magliano, M. P. & Maitra, A. Pancreatic cancer: advances and challenges. Cell 186, 1729–1754 (2023).
Google Scholar
Desai, S. A. et al. The tumor microenvironment: shaping cancer progression and treatment response. J. Chemother. 37, 1–30 (2023).
Lee, D. U., Han, B. S., Jung, K. H. & Hong, S.-S. Tumor stroma as a therapeutic target for pancreatic ductal adenocarcinoma. Biomol. Ther. 32, 281–290 (2024).
Google Scholar
Wang, H. et al. Shaping the immune-suppressive microenvironment on tumor-associated myeloid cells through tumor-derived exosomes. Int. J. Cancer 154, 2031–2042 (2024).
Google Scholar
Ju, Y. et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 8, 199 (2024).
Google Scholar
Zhang, S. et al. Fatty acid metabolism of immune cells: a new target of tumour immunotherapy. Cell Death Discov. 10, 39 (2024).
Google Scholar
Zhao, F. et al. Paracrine Wnt5a-β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity 48, 147–160.e147 (2018).
Google Scholar
Jin, H. R. et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J. Hematol. Oncol. 16, 103 (2023).
Google Scholar
Hogg, G. D. et al. Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer. Sci. Immunol. 10, eadp3978 (2025).
Google Scholar
Zeltz, C. et al. Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin.Cancer Biol. 62, 166–181 (2020).
Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527–540 (2020).
Google Scholar
Lohneis, P. et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur. J. Cancer 83, 290–301 (2017).
Google Scholar
Acuto, O. & Michel, F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939–951 (2003).
Google Scholar
Wilfahrt, D. & Delgoffe, G. M. Metabolic waypoints during T cell differentiation. Nat. Immunol. 25, 206–217 (2024).
Google Scholar
Liu, Y. et al. Regulation of CD4+ T cell differentiation and function by glucose metabolism. Genes Immun. 26, 287–296 (2025).
Google Scholar
Su, X. et al. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. J. Transl. Med. 22, 751 (2024).
Google Scholar
Burke, K. P., Chaudhri, A., Freeman, G. J. & Sharpe, A. H. The B7: CD28 family and friends: unraveling coinhibitory interactions. Immunity 57, 223–244 (2024).
Google Scholar
Kim, H.-J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol. Res. 2, 91–98 (2014).
Google Scholar
Patterson, M. T. et al. Tumor-specific CD4 T cells instruct monocyte fate in pancreatic ductal adenocarcinoma. Cell Rep. 42, 112732 (2023).
Google Scholar
Speiser, D. E., Chijioke, O., Schaeuble, K. & Münz, C. CD4+ T cells in cancer. Nat. Cancer 4, 317–329 (2023).
Google Scholar
Ali, L. R. et al. PD-1 blockade induces reactivation of Nonproductive T-cell responses characterized by NF-κB Signaling In Patients With Pancreatic Cancer. Clin. Can. Res. 30, 542–553 (2024).
Google Scholar
Weinstein, A. G. & DeNardo, D. G. Targeting dendritic cells to drive PDAC immunotherapy response. Trends Pharm. Sci. 45, 1095–1096 (2024).
Google Scholar
Falcomatà, C. et al. Context-specific determinants of the immunosuppressive tumor microenvironment in pancreatic cancer. Cancer Discov. 13, 278–297 (2023).
Google Scholar
Bhatia, R. et al. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment. Semin Cancer Biol. 86, 499–510 (2022).
Google Scholar
Reddy, D. S. et al. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions. Cytokine Growth Factor Rev. 71-72, 26–39 (2023).
Google Scholar
Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423–5434 (2006).
Google Scholar
Smith, H., Arbe-Barnes, E., Shah, E. A. & Sivakumar, S. Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?. Front. Immunol. 15, 1406250 (2024).
Google Scholar
Suzuki, K. et al. Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker. Preprint at https://doi.org/10.1101/2023.05.24.542137 (2023).
Sivakumar, S. et al. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Nat. Commun. 16, 1397 (2025).
Google Scholar
Nagira, Y. et al. S-531011, a novel anti-human CCR8 antibody, induces potent antitumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells. Mol. Cancer Ther. 22, 1063–1072 (2023).
Google Scholar
Barsheshet, Y. et al. CCR8(+)FOXp3(+) T(reg) cells as master drivers of immune regulation. Proc. Natl. Acad. Sci. USA 114, 6086–6091 (2017).
Google Scholar
Kidani, Y. et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proc. Natl. Acad. Sci. USA 119, e2114282119 (2022).
Google Scholar
Weaver, J. D. et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunol 11, 2141007 (2022).
Google Scholar
Alissafi, T. et al. Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells. J. Autoimmun. 104, 102310 (2019).
Google Scholar
Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA 118, e2023739118 (2021).
Google Scholar
Bengsch, F. et al. CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Cancer Immunol. Immunother. 66, 1609–1617 (2017).
Google Scholar
Anu, R., Shiu, K.-K. & Khan, K. H. The immunomodulatory role of IDO1-Kynurenine-NAD+ pathway in switching cold tumor microenvironment in PDAC. Front. Oncol. 13, 1142838 (2023).
Google Scholar
Li, W. et al. Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications. Mol. Biomed. 6, 1–37 (2025).
Google Scholar
Mundry, C. S. et al. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals. Cancer Lett. 607, 217321 (2024).
Google Scholar
Masmoudi, D., Villalba, M. & Alix-Panabières, C. Natural killer cells: the immune frontline against circulating tumor cells. J. Exp. Clin. Cancer Res. 44, 1–15 (2025).
Google Scholar
Cui, H. et al. The dynamic shifts of IL-10-producing Th17 and IL-17-producing Treg in health and disease: a crosstalk between ancient” Yin-Yang” theory and modern immunology. Cell Commun. Signal. 22, 99 (2024).
Google Scholar
Yofe, I. et al. Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling. Nat. Cancer 3, 1336–1350 (2022).
Google Scholar
Watanabe, T. et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 114, 1859–1870 (2023).
Google Scholar
Wu, A. A. et al. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunol 4, e1016700 (2015).
Google Scholar
Picard, F. S. R. et al. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Gut 72, 1510–1522 (2023).
Google Scholar
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
Google Scholar
Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1–10 (2025).
Google Scholar
Xing, X. et al. B4GALT5 inhibits CD8(+) T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. J. Immunother. Cancer 13, e010908 (2025).
Google Scholar
Marcon, F. et al. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunol 9, 1845424 (2020).
Google Scholar
Zhu, A., Bai, Y., Nan, Y. & Ju, D. Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy. Clin. Transl. Med. 14, e70046 (2024).
Google Scholar
Moretta, A. et al. NK cells at the interface between innate and adaptive immunity. Cell Death Diff. 15, 226–233 (2008).
Google Scholar
Carlomagno, S., Setti, C., Ortolani, F. & Sivori, S. Pancreatic ductal adenocarcinoma microenvironment: soluble factors and cancer associated fibroblasts as modulators of NK cell functions. Immunol. Lett. 269, 106898 (2024).
Google Scholar
Fanijavadi, S., Thomassen, M. & Jensen, L. H. Targeting triple NK cell suppression mechanisms: a comprehensive review of biomarkers in pancreatic cancer therapy. Int. J. Mol. Sci. 26, 515 (2025).
Google Scholar
Rahimi, A. et al. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies. Cancer Cell Int. 23, 312 (2023).
Google Scholar
Demircioglu, F. et al. Cancer associated fibroblast FAK regulates malignant cell metabolism. Nat. Commun. 11, 1290 (2020).
Google Scholar
Kwantwi, L. B. & Tandoh, T. Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: Implications for cancer-associated therapies and tumor progression. Clin. Transl. Oncol. 27, 1–8 (2024).
Google Scholar
Zhang, W. et al. MDSCs in sepsis-induced immunosuppression and its potential therapeutic targets. Cytokine Growth Factor Rev. 69, 90–103 (2023).
Google Scholar
Sarangi, P. Role of indoleamine 2, 3-dioxygenase 1 in immunosuppression of breast cancer. Cancer Pathog. Ther. 2, 246–255 (2024).
Google Scholar
Muthalagu, N. et al. Repression of the type I interferon pathway underlies MYC-and KRAS-dependent evasion of NK and B cells in pancreatic ductal adenocarcinoma. Cancer Discov. 10, 872–887 (2020).
Google Scholar
Briercheck, E. L. et al. PTEN is a negative regulator of NK cell cytolytic function. J. Immunol. 194, 1832–1840 (2015).
Google Scholar
Freed-Pastor, W. A. et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer cell. 39, 1342–1360.e1314 (2021).
Google Scholar
Moore, A. M. et al. NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition. Proc. Natl. Acad. Sci. USA 118, e2012469118 (2021).
Google Scholar
Liu, P., Jacques, J. & Hwang, C.-I. Epigenetic landscape of DNA methylation in pancreatic ductal adenocarcinoma. Epigenomes 8, 41 (2024).
Google Scholar
Kumar, V. & Mahato, R. I. Natural killer cells for pancreatic cancer immunotherapy: role of nanoparticles. Cancer Lett. 579, 216462 (2023).
Google Scholar
Dai, Z. et al. Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice. J. Clin. Investig. 135, e179014 (2025).
Google Scholar
Abodunrin, F., Olson, D. J., Emehinola, O. & Bestvina, C. M. Adopting tomorrow’s therapies today: a perspective review of adoptive cell therapy in lung cancer. Ther. Adv. Med. Oncol. 17, 17588359251320280 (2025).
Google Scholar
Page, A., Chuvin, N., Valladeau-Guilemond, J. & Depil, S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol. Immunol. 21, 315–331 (2024).
Google Scholar
Hosseinalizadeh, H. et al. Emerging combined CAR-NK cell therapies in cancer treatment: finding a dancing partner. Mol. Ther. 33, 2406–2425 (2025).
Google Scholar
Li, H.-B., Yang, Z.-H. & Guo, Q.-Q. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Commun. Signal. 19, 1–13 (2021).
Google Scholar
Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 1–22 (2021).
Google Scholar
Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target Ther. 6, 412 (2021).
Google Scholar
Bawden, E. & Gebhardt, T. The multifaceted roles of CD4+ T cells and MHC class II in cancer surveillance. Curr. Opin. Immunol. 83, 102345 (2023).
Google Scholar
Aggarwal, V., Workman, C. J. & Vignali, D. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415–1422 (2023).
Google Scholar
Pan, Y. et al. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma. Front Endocrinol. 14, 1181538 (2023).
Google Scholar
Mishra, S. et al. T cell exhaustion and activation markers in pancreatic cancer: a systematic review. J. Gastrointest. Cancer 55, 1–19 (2023).
Li, E. et al. Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15, 135–147 (2023).
Google Scholar
Das, M., Zhu, C. & Kuchroo, V. K. Tim‐3 and its role in regulating anti‐tumor immunity. Immunol. Rev. 276, 97–111, (2017).
Gulhati, P. et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat. Cancer 4, 62–80 (2023).
Google Scholar
Wang, J. et al. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Cancer Lett. 573, 216366 (2023).
Google Scholar
Li, K. et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. 40, 1374–1391.e1377 (2022).
Google Scholar
Luo, W., Wen, T. & Qu, X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J. Exp. Clin. Cancer Res. 43, 8 (2024).
Google Scholar
Piro, G. et al. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Br. J. Cancer 128, 331–341 (2023).
Google Scholar
Parikh, A. R. et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat. Cancer 2, 1124–1135 (2021).
Google Scholar
Shen, Y. et al. Oncolytic virus VG161 in refractory hepatocellular carcinoma. Nature 641, 503–511 (2025).
Google Scholar
Chung, V. et al. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist 30, oyae323 (2025).
Google Scholar
Yi, L. et al. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial. Signal Transduct. Target Ther. 9, 347 (2024).
Google Scholar
Li, J. et al. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer. Cancer Immunol. Immunother. 73, 219 (2024).
Google Scholar
Cheng, Y. et al. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunol. Immunother. 74, 83 (2025).
Google Scholar
Hüttner, F. J. et al. Pancreatic resection with perioperative drug repurposing of propranolol and etodolac – the phase II randomized controlled PROSPER trial. Langenbecks Arch. Surg. 410, 168 (2025).
Google Scholar
Kamath, S. D. et al. Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study. Oncologist 25, e808–e815 (2020).
Google Scholar
Akhuba, L., Tigai, Z. & Shek, D. Where do we stand with immunotherapy for advanced pancreatic ductal adenocarcinoma: a synopsis of clinical outcomes. Biomedicines 10, 3196 (2022).
Google Scholar
Kole, C. et al. Immunotherapy in combination with well-established treatment strategies in pancreatic cancer: current insights. Cancer Manag Res. 14, 1043–1061 (2022).
Google Scholar
Liu, L. et al. Combination therapy for pancreatic cancer: anti-PD-(L) 1-based strategy. J. Exp. Clin. Cancer Res. 41, 56 (2022).
Google Scholar
Henriksen, A., Dyhl-Polk, A., Chen, I. & Nielsen, D. Checkpoint inhibitors in pancreatic cancer. Cancer Treat. Rev. 78, 17–30 (2019).
Google Scholar
Gössling, G. C., Zhen, D. B., Pillarisetty, V. G. & Chiorean, E. G. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Expert Rev. Clin. Immunol. 18, 1173–1186 (2022).
Google Scholar
Murphy, J. F. Therapeutic vaccination and cancer immunotherapy. J. Explor Res. Pharmacol. 9, 8–12 (2024).
Google Scholar
Ullman, N. A., Burchard, P. R., Dunne, R. F. & Linehan, D. C. Immunologic strategies in pancreatic cancer: making cold tumors hot. J. Clin. Oncol. 40, 2789–2805 (2022).
Google Scholar
Kirtane, K., Elmariah, H., Chung, C. H. & Abate-Daga, D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J. Immunother. Cancer 9, e002723 (2021).
Google Scholar
Yi, M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol. Cancer 21, 28 (2022).
Google Scholar
Herting, C. J., Karpovsky, I. & Lesinski, G. B. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions. Cancer Metastasis Rev. 40, 1–15 (2021).
Google Scholar
Li, Y., Sharma, A. & Schmidt-Wolf, I. G. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer. Mol. Cancer 23, 80 (2024).
Google Scholar
Gros, A. et al. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J. Clin. Investig. 124, 2246–2259 (2014).
Google Scholar
Melero, I. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Google Scholar
Bhattacharjee, K., Sengupta, A., Kumar, R. & Ghosh, A. Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study. Front. Bioinform. 5, 1536783 (2025).
Google Scholar
Milán, M. Chromosomal instability in development and disease: Beyond cancer evolution. Curr. Opin. Cell Biol. 95, 102537 (2025).
Google Scholar
Chen, X. et al. Chromosomal instability as a driver of cancer progression. Nat. Rev. Genet. 26, 31–46 (2025).
Google Scholar
Zhong, L., Zhao, Z. & Zhang, X. Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study. Signal Transduct. Target Ther. 8, 363 (2023).
Google Scholar
Johnson, C., Burkhart, D. L. & Haigis, K. M. Classification of KRAS-Activating mutations and the implications for therapeutic intervention. Cancer Discov. 12, 913–923 (2022).
Google Scholar
Jain, K. & Rana, R. in Adv Can Biomark Res (eds A. N. Singh, R. Rana, & S. Nayak) 3, 47–63 (Academic Press, 2025).
Higashijima, Y. et al. Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells. EMBO J. 39, e103949 (2020).
Google Scholar
Liu, R. et al. Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets. MedComm 4, e292 (2023).
Google Scholar
Liu, Y. et al. FOXA1 O-GlcNAcylation–mediated transcriptional switch governs metastasis capacity in breast cancer. Sci. Adv. 9, eadg7112 (2023).
Google Scholar
Jones, P. A. & Gonzalgo, M. L. Altered DNA methylation and genome instability: a new pathway to cancer?. Proc. Natl. Acad. Sci. USA 94, 2103–2105 (1997).
Google Scholar
Sergeeva, A., Davydova, K., Perenkov, A. & Vedunova, M. Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology. Gene 875, 147487 (2023).
Google Scholar
Espinet, E., Klein, L., Puré, E. & Singh, S. K. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer 8, 1060–1071 (2022).
Google Scholar
Ala, M. Target c-Myc to treat pancreatic cancer. Cancer Biol. Ther. 23, 34–50 (2022).
Google Scholar
Casacuberta-Serra, S., González-Larreategui, Í, Capitán-Leo, D. & Soucek, L. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer. Signal Transduct. Target Ther. 9, 205 (2024).
Google Scholar
Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 386 (2021).
Google Scholar
Juiz, N. et al. Basal-like and classical cells coexist in pancreatic cancer revealed by single-cell analysis on biopsy-derived pancreatic cancer organoids from the classical subtype. FASEB J. 34, 12214–12228 (2020).
Google Scholar
Chen, Y., Liu, Q. -p, Xie, H. & Ding, J. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta Pharm. Sin. 45, 686–703 (2024).
Google Scholar
Isermann, T., Sers, C., Der, C. J. & Papke, B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer 11, 91–116 (2025).
Google Scholar
Bahar, M. E., Kim, H. J. & Kim, D. R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct. Target Ther. 8, 455 (2023).
Google Scholar
Kahvecioglu, D. A comprehensive review of RAF kinase: advances in inhibition strategies for drug development. J. Mol. Struct. 1337, 142206 (2025).
Google Scholar
Zhang, J. et al. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: recent advancements provide hope (Review). Oncol. Rep. 50, 206 (2023).
Google Scholar
Haidar, M. & Jacquemin, P. Past and future strategies to inhibit membrane localization of the KRAS oncogene. Int. J. Mol. Sci. 22, 13193 (2021).
Google Scholar
Klochkov, S. G. et al. Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. Semin Cancer Biol. 56, 128–134 (2019).
Google Scholar
Shi, Y. et al. Targeting KRAS: from metabolic regulation to cancer treatment. Mol. Cancer 24, 9 (2025).
Google Scholar
Liu, J. et al. Glycolysis regulates KRAS plasma membrane localization and function through defined glycosphingolipids. Nat. Commun. 14, 465 (2023).
Google Scholar
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
Google Scholar
Hoang, T. & Tsang, E. S. Advances in novel targeted therapies for pancreatic adenocarcinoma. J. Gastrointest. Cancer 56, 38 (2025).
Google Scholar
Goodwin, C. M. et al. Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83, 141–157 (2023).
Google Scholar
Yavas, A. et al. SWI/SNF complex-deficient undifferentiated carcinoma of the pancreas: clinicopathologic and genomic analysis. Mod. Pathol. 37, 100585 (2024).
Google Scholar
Amintas, S. et al. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Sci. Rep. 12, 2976 (2022).
Google Scholar
Knox, J. J. et al. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Nat. Commun. 16, 5919 (2025).
Google Scholar
Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).
Google Scholar
Mody, J. & Kamgar, M. Pancreatic adenocarcinoma with Co-occurrence of KRAS and EGFR mutations: case report and literature review. Case Rep. Oncol. 17, 399–406 (2024).
Google Scholar
van Duijvenvoorde, M. et al. Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy. Clin. Transl. Immunol. 11, e1363 (2022).
Google Scholar
Gupta, M. et al. Targeting the NTRK fusion gene in pancreatic acinar cell carcinoma: a case report and review of the literature. J. Natl. Compr. Cancer Netw. 19, 10–15 (2021).
Google Scholar
Lena, J. et al. Extensive molecular profiling of KRAS wild-type as compared to KRAS mutated pancreatic ductal adenocarcinoma on 318 patients. Eur. J. Cancer 216, 115197 (2025).
Google Scholar
Bonilla, C. E. et al. Exceptional response to multimodal therapy in stage IV pancreatic ductal adenocarcinoma: a case report and review. Cureus 17, e87044 (2025).
Google Scholar
Kalamara, V. & Garinis, G. A. The epitranscriptome: reshaping the DNA damage response. Trends Cell Biol. 35, 294–304 (2025).
Google Scholar
Jachimowicz, R. D., Goergens, J. & Reinhardt, H. C. DNA double-strand break repair pathway choice – from basic biology to clinical exploitation. Cell Cycle 18, 1423–1434 (2019).
Google Scholar
Elbakry, A. & Löbrich, M. Homologous recombination subpathways: a tangle to resolve. Front. Genet. 12, 723847 (2021).
Google Scholar
Ortega, R., Bitler, B. G. & Arnoult, N. Multiple functions of PARP1 in the repair of DNA double strand breaks. DNA Repair. 152, 103873 (2025).
Google Scholar
Eisemann, T. & Pascal, J. M. Poly(ADP-ribose) polymerase enzymes and the maintenance of genome integrity. Cell Mol. Life Sci. 77, 19–33 (2020).
Google Scholar
Rouleau-Turcotte, É & Pascal, J. M. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification. J. Biol. Chem. 299, 105397 (2023).
Google Scholar
Hurtado-Bagès, S., Knobloch, G., Ladurner, A. G. & Buschbeck, M. The taming of PARP1 and its impact on NAD(+) metabolism. Mol. Metab. 38, 100950 (2020).
Google Scholar
Fu, X. et al. BRCA1 and breast cancer: molecular mechanisms and therapeutic strategies. Front. Cell Dev. Biol. 10, 813457 (2022).
Google Scholar
Chi, J. et al. The role of PARP inhibitors in BRCA mutated pancreatic cancer. Ther. Adv. Gastroenterol. 14, 17562848211014818 (2021).
Google Scholar
Wang, R. et al. Combating tumor PARP inhibitor resistance: Combination treatments, nanotechnology, and other potential strategies. Int. J. Pharm. 669, 125028 (2025).
Google Scholar
Huang, R.-X. & Zhou, P.-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct. Target Ther. 5, 60 (2020).
Google Scholar
Williams, R. S., Williams, J. S. & Tainer, J. A. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem. Cell Biol. 85, 509–520 (2007).
Google Scholar
Wang, Y.-L. et al. MRNIP condensates promote DNA double-strand break sensing and end resection. Nat. Commun. 13, 2638 (2022).
Google Scholar
Meng, F. et al. Base-excision repair pathway regulates transcription-replication conflicts in pancreatic ductal adenocarcinoma. Cell Rep. 43, 114820 (2024).
Google Scholar
Qiu, Z., Oleinick, N. L. & Zhang, J. ATR/CHK1 inhibitors and cancer therapy. Radiother. Oncol. 126, 450–464 (2018).
Google Scholar
Moosavi, F. et al. Targeting DNA damage response in pancreatic ductal adenocarcinoma: a review of preclinical and clinical evidence. Biochim. Biophys. Acta Rev. Cancer 1879, 189185 (2024).
Google Scholar
Shah, A., Johnson, E., Ponnusamy, M. P. & Batra, S. K. Emerging pathways yielding opportunities for future treatments in pancreatic ductal adenocarcinoma. Expert Opin. Ther. Targets 29, 309–326 (2025).
Google Scholar
Godet, I. & Gilkes, D. M. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr. Cancer Sci. Ther. 4, 10–15761 (2017).
Javle, M. et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 7, 693–699 (2021).
Google Scholar
Hernando-Calvo, A. et al. A phase II, open-label, randomized trial of Durvalumab With Olaparib or Cediranib in patients with mismatch repair-proficient colorectal or pancreatic cancer. Clin. Colorectal Cancer 23, 272–284.e279 (2024).
Google Scholar
Zhao, K. et al. Neoadjuvant Pembrolizumab enables successful downstaging and resection of borderline resectable MSI-H/dMMR pancreatic ductal adenocarcinoma: a case report and literature review. J. Gastrointest. Cancer 56, 112 (2025).
Google Scholar
Pishvaian, M. J. et al. A phase I/II study of Veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer. Clin. Cancer Res. 26, 5092–5101 (2020).
Google Scholar
Yakushina, V. et al. Microsatellite instability detection: the current standards, limitations, and misinterpretations. JCO Precis. Oncol. 7, e2300010, (2023).
Stefanoudakis, D. et al. Significance of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer. Curr. Issues Mol. Biol. 46, 2827–2844 (2024).
Google Scholar
Mandal, J., Mandal, P., Wang, T.-L. & Shih, I.-M. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response. J. Biomed. Sci. 29, 71 (2022).
Google Scholar
Centore, R. C. et al. Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 36, 936–950 (2020).
Google Scholar
Duan, X. et al. The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications. Front. Immunol. 15, 1495221 (2024).
Google Scholar
Yang, X. J. & Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310–5318 (2007).
Google Scholar
Galassi, C. et al. Epigenetic regulation of cancer stemness. Signal Transduct. Target Ther. 10, 243 (2025).
Google Scholar
Narita, T. et al. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol. Cell. 81, 2166–2182.e2166 (2021).
Google Scholar
Mortoglou, M. et al. Non-coding RNAs in pancreatic ductal adenocarcinoma: new approaches for better diagnosis and therapy. Transl. Oncol. 14, 101090 (2021).
Google Scholar
Frampton, A. E. et al. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur. J. Cancer 51, 1389–1404 (2015).
Google Scholar
Girolimetti, G. et al. Dysregulation of a subset of circulating and vesicle-associated miRNA in pancreatic cancer. Noncoding RNA 10, 29 (2024).
Google Scholar
Meng, Q. et al. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance. Theranostics 10, 3967–3979 (2020).
Google Scholar
Xiong, M. et al. The diagnostic and prognostic values of microRNA-196a in cancer. Biosci. Rep. 41, BSR20203559 (2021).
Google Scholar
Liu, D. S. K. et al. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. J. Exp. Clin. Cancer Res. 43, 189 (2024).
Google Scholar
Di Martino, M. T. et al. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review. Mol. Ther. Nucleic Acids 27, 1191–1224 (2022).
Google Scholar
Taniguchi, T. et al. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. DEN Open. 4, e333 (2024).
Google Scholar
Godfrey, J. D. et al. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Cell Death Dis. 9, 644 (2018).
Google Scholar
Long, L. M. et al. The clinical significance of miR-34a in Pancreatic Ductal Carcinoma And Associated Molecular And Cellular Mechanisms. Pathobiol 84, 38–48 (2017).
Google Scholar
Sharma, N. S. et al. Long non-coding RNA GAS5 acts as proliferation “brakes” in CD133+ cells responsible for tumor recurrence. Oncogenesis 8, 68 (2019).
Google Scholar
Good, K. V., Vincent, J. B. & Ausió, J. MeCP2: the genetic driver of rett syndrome epigenetics. Front. Genet. 12, 620859 (2021).
Google Scholar
Dana, H. et al. Molecular mechanisms and biological functions of siRNA. Int J. Biomed. Sci. 13, 48–57 (2017).
Google Scholar
Xu, T. et al. DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p. World J. Gastroenterol. 26, 1745–1757 (2020).
Google Scholar
Zhuo, C. et al. Computational biological analysis reveals that HIF-1 and FoxO signaling pathways influence cognitive impairment in patients with depression. Transl. Psychiatry 15, 518 (2025).
Google Scholar
Kubo, M. et al. Impact of CD36 on chemoresistance in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 27, 610–619 (2020).
Google Scholar
Ko, A. et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br. J. Cancer 93, 195–199 (2005).
Google Scholar
Wang, L., Mu, N. & Qu, N. Methylation of the miR‑29b‑3p promoter contributes to angiogenesis, invasion, and migration in pancreatic cancer. Oncol. Rep. 45, 65–72 (2021).
Google Scholar
Shi, X. et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal Transduct. Target Ther. 9, 192 (2024).
Google Scholar
Yamashita, A. & Takeuchi, O. Translational control of mRNAs by 3’-Untranslated region binding proteins. BMB Rep. 50, 194–200 (2017).
Google Scholar
Scullion, K. M. et al. Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. iScience 24, 101937 (2021).
Google Scholar
Haab, B. et al. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Cancer Lett. 604, 217245 (2024).
Google Scholar
Metcalf, G. A. D. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene 43, 2135–2142 (2024).
Google Scholar
Prasad, M., Hamsa, D., Fareed, M. & Karobari, M. I. An update on the molecular mechanisms underlying the progression of miR-21 in oral cancer. World J. Surg. Oncol. 23, 73 (2025).
Google Scholar
Chen, C. et al. Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching. Cell Death Dis. 13, 682 (2022).
Google Scholar
Kannampuzha, S. & Gopalakrishnan, A. V. Cancer chemoresistance and its mechanisms: associated molecular factors and its regulatory role. Med. Oncol. 40, 264 (2023).
Google Scholar
Li, H. et al. Targeting Non-BET bromodomains: emerging opportunities in drug discovery. J. Med. Chem. 68, 24730–24758 (2025).
Google Scholar
Ma, M., An, J., Jiang, T. & Xie, K. GATA6 in pancreatic cancer initiation and progression. Genes Dis. 12, 101353 (2025).
Google Scholar
Zhou, E. et al. GATA6 amplification is associated with improved survival in TP53-mutated unresectable pancreatic cancer. Pancreas 54, e303–e309 (2025).
Google Scholar
Kloesch, B. et al. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Gut 71, 766–777 (2022).
Google Scholar
Greendyk, J. D. et al. Association between SMAD4 mutations and GATA6 expression in paired pancreatic ductal adenocarcinoma tumor specimens: data from two independent molecularly-characterized cohorts. Biomedicines 11, 3058 (2023).
Google Scholar
Giri, S. S., Tripathi, A. S., Erkekoğlu, P. & Zaki, M. E. Molecular pathway of pancreatic cancer-associated neuropathic pain. J. Biochem. Mol. Toxicol. 38, e23638 (2024).
Google Scholar
Na’ara, S., Amit, M. & Gil, Z. L1CAM induces perineural invasion of pancreas cancer cells by upregulation of metalloproteinase expression. Oncogene 38, 596–608 (2019).
Google Scholar
Deb, V. K., Chauhan, N. & Jain, U. Deciphering TGF-β1’s role in drug resistance and leveraging plant bioactives for cancer therapy. Eur. J. Pharmacol. 988, 177218 (2025).
Google Scholar
Grage-Griebenow, E. et al. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Mol. Oncol. 8, 982–997 (2014).
Google Scholar
Lei, Z.-N. et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct. Target Ther. 7, 358 (2022).
Google Scholar
Singh, D. Synergistic inhibition of KRAS-driven pancreatic cancer using siRNA-loaded nanoparticles with erlotinib: a comprehensive in vitro investigation. BioNanoSci 15, 343 (2025).
Google Scholar
Vaccaro, V. et al. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J. Gastroenterol. 19, 4511–4519 (2013).
Google Scholar
Cai, W. Q. et al. The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front. Oncol. 10, 1249 (2020).
Google Scholar
Liermann, J. et al. Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: long-term results of the randomized controlled phase II PARC trial. Clin. Transl. Oncol. 34, 15–22 (2022).
Google Scholar
Arai, H. et al. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: a phase II trial (HYBRID). Cancer Med. 13, e7107 (2024).
Google Scholar
Matsumura, M. et al. A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. Langenbecks Arch. Surg. 407, 1345–1356 (2022).
Google Scholar
Sanghvi, S. M. et al. A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. J. Gastrointest. Oncol. 13, 1989–1996 (2022).
Google Scholar
Denduluri, S. K. et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2, 13–25 (2015).
Google Scholar
Abdel-Wahab, R. et al. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J. Hematol. Oncol. 11, 71 (2018).
Google Scholar
Han, S. et al. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia 59, 101070 (2025).
Google Scholar
Hong, Z. et al. Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. J. Exp. Clin. Cancer Res. 44, 68 (2025).
Google Scholar
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I. & Pourgholami, M. H. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur. J. Pharmacol. 949, 175586 (2023).
Google Scholar
Wang, F. et al. Safety, pharmacokinetics, and pharmacodynamics evaluation of ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, in chinese patients with advanced solid tumors. Cancer Med. 14, e70653 (2025).
Google Scholar
Kulke, M. H. et al. Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocr. Relat. Cancer 29, 335–344 (2022).
Google Scholar
Perez, K. et al. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. Oncologist 30, oyae364 (2025).
Google Scholar
Halperin, D. M. et al. Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial. JAMA Oncol. 8, 904–909 (2022).
Google Scholar
Lanfredini, S., Thapa, A. & O’Neill, E. RAS in pancreatic cancer. Biochem. Soc. Trans. 47, 961–972 (2019).
Google Scholar
Chao, M. W. et al. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status. Clin. Epigenetics. 11, 85 (2019).
Google Scholar
Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33–43 (2023).
Google Scholar
Cho, B. C. et al. D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial. Nat. Med. 31, 2768–2777 (2025).
Google Scholar
van Brummelen, E. M. J. et al. Phase I study of Afatinib and Selumetinib in patients with KRAS-mutated colorectal, non-small cell lung, and pancreatic cancer. Oncologist 26, 290–e545 (2021).
Google Scholar
Zhu, X. et al. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: biomarker analysis of a randomized phase 2 trial. Radiother. Oncol. 190, 109941 (2024).
Google Scholar
Jain, A. et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer. Cancer Res. 79, 4491–4502 (2019).
Google Scholar
Dogaru, B. G. & Munteanu, C. The role of hydrogen sulfide (H(2)S) in epigenetic regulation of neurodegenerative diseases: a systematic review. Int. J. Mol. Sci. 24, 12555 (2023).
Google Scholar
Hu, X. et al. New possible silver lining for pancreatic cancer therapy: hydrogen sulfide and its donors. Acta Pharm. Sin. B. 11, 1148–1157 (2021).
Google Scholar
Ahmed, A. A., Haider, S., Arshad, T. & Neidle, S. Structure-activity relationships for the pan-quadruplex experimental drug QN-302 and two analogs probed with comparative transcriptome profiling and molecular modeling. Cancer Res. 84, 5928–5928 (2024).
Google Scholar
Luo, W. et al. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. Cancer Med. 8, 6403–6413 (2019).
Google Scholar
Park, S. J. et al. ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy. Arch. Pharm. Res. 44, 1062–1075 (2021).
Google Scholar
Romeo, M. A. et al. VPA and TSA interrupt the interplay between mutp53 and HSP70, leading to CHK1 and RAD51 down-regulation and sensitizing pancreatic cancer cells to AZD2461 PARP Inhibitor. Int. J. Mol. Sci. 23, 2268 (2022).
Google Scholar
Mottini, C. et al. Predictive signatures inform the effective repurposing of decitabine to treat KRAS–dependent pancreatic ductal adenocarcinoma. Cancer Res. 79, 5612–5625 (2019).
Google Scholar
Sugimoto, H. et al. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov. 1, 1–10 (2015).
Google Scholar
Espona-Fiedler, M. et al. Overcoming therapy resistance in pancreatic cancer: new insights and future directions. Biochem. Pharmacol. 229, 116492 (2024).
Google Scholar
Soragni, A. et al. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat. Rev. Cancer 25, 613–633 (2025).
Google Scholar
Wang, Y. et al. NRP1 overexpression potentially enhances osimertinib resistance in NSCLC via activation of the PI3K/AKT signaling pathway. Am. J. Cancer Res. 14, 5680–5696 (2024).
Google Scholar
Nussinov, R., Zhang, M. & Jang, H. RAS signaling in the PI3K/AKT/MTOR Pathway. Biophys. J. 118, 51a (2020).
Google Scholar
Brägelmann, J. et al. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nat. Commun. 12, 5505 (2021).
Google Scholar
Jiang, M. et al. PI3K/AKT/mTOR axis in cancer: from pathogenesis to treatment. MedComm 6, e70295 (2025).
Google Scholar
Chen, D. et al. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma. Int. J. Mol. Sci. 13, 1186–1208 (2012).
Google Scholar
Dieli, R. et al. The Oncoprotein Mucin 1 in pancreatic cancer onset and progression: potential clinical implications. Biomolecules 15, 275 (2025).
Google Scholar
Skrypek, N. et al. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Oncogene 32, 1714–1723 (2013).
Google Scholar
Liu, F. T. & Stowell, S. R. The role of galectins in immunity and infection. Nat. Rev. Immunol. 23, 479–494 (2023).
Google Scholar
Farran, B. & Nagaraju, G. P. Exosomes as therapeutic solutions for pancreatic cancer. Drug Discov. Today 25, 2245–2256 (2020).
Google Scholar
Malla, R., Mangam, C. & Nagaraju, G. P. Pancreatic cancer exosomes: their role in drug resistance and immunomodulation. Cytokine Growth Factor Rev. 86, 108–120 (2025).
Google Scholar
André Mdo, R., Pedro, A. & Lyden, D. Cancer exosomes as mediators of drug resistance. Methods Mol. Biol. 1395, 229–239 (2016).
Google Scholar
Li, J. T., Wang, Y. P., Yin, M. & Lei, Q. Y. Metabolism remodeling in pancreatic ductal adenocarcinoma. Cell Stress. 3, 361–368 (2019).
Google Scholar
Fan, P. et al. Alleviating hypoxia to improve cancer immunotherapy. Oncogene 42, 3591–3604 (2023).
Google Scholar
Murthy, D. et al. The MUC1-HIF-1α signaling axis regulates pancreatic cancer pathogenesis through polyamine metabolism remodeling. Proc. Natl. Acad. Sci. USA 121, e2315509121 (2024).
Google Scholar
Chen, K. et al. The metabolic flexibility of quiescent CSC: implications for chemotherapy resistance. Cell Death Dis. 12, 835 (2021).
Google Scholar
Park, J.-M., Lee, D.-H. & Kim, D.-H. Redefining the role of AMPK in autophagy and the energy stress response. Nat. Commun. 14, 2994 (2023).
Google Scholar
Sarfaty, E. et al. Surgical management of pancreatic ductal adenocarcinoma: a narrative review. Transl. Gastroenterol. Hepatol. 8, 39 (2023).
Google Scholar
Sentí Farrarons, S. et al. Venous resection in pancreatic oncologic surgery: different techniques for different situations. Cir. Esp. (Engl. Ed.). 101, 816–823 (2023).
Google Scholar
Mas, L., Schwarz, L. & Bachet, J. B. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr. Opin. Oncol. 32, 356–363 (2020).
Google Scholar
de Jong, E. J. M. et al. Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. Int. J. Cancer 150, 1654–1663 (2022).
Google Scholar
Bauer, K., Henne-Bruns, D. & Manzini, G. Analysis of the CONKO-001 trial: is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer?. Int. J. Risk Saf. Med. 34, 29–40 (2023).
Google Scholar
Peshin, S. et al. Advances in the management of pancreatic cancer: current strategies and emerging therapies. Int. J. Mol. Sci. 26, 7055 (2025).
Google Scholar
Zhong, W. Z. et al. Erlotinib versus gemcitabine plus Cisplatin as Neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J. Clin. Oncol. 37, 2235–2245 (2019).
Google Scholar
Tempero, M. A. et al. Adjuvant nab-Paclitaxel + Gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J. Clin. Oncol. 41, 2007–2019 (2023).
Google Scholar
Natu, J. & Nagaraju, G. P. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: special focus on resistance mechanisms and metronomic therapies. Cancer Lett. 573, 216382 (2023).
Google Scholar
Keane, F. et al. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. J. Natl. Cancer Inst. 117, 496–506 (2025).
Google Scholar
Levink, I. J. M. et al. Neoantigen quantity and quality in relation to pancreatic cancer survival. Front. Med. 8, 751110 (2021).
Google Scholar
Hu, H. -f et al. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Acta Pharm. Sin. 42, 1725–1741 (2021).
Google Scholar
Orgován, Z. & Keserű, G. M. Small molecule inhibitors of RAS proteins with oncogenic mutations. Cancer Metastasis Rev. 39, 1107–1126 (2020).
Google Scholar
Wei, D. et al. A small molecule with big impact: MRTX1133 targets the KRASG12D mutation in pancreatic cancer. Clin. Cancer Res. 30, 655–662 (2024).
Google Scholar
Hong, D. S. et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207–1217 (2020).
Google Scholar
McAndrews, K. M. et al. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci. Alliance 4, e202000875 (2021).
Google Scholar
Kudo, Y. et al. Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells. J. Biochem. 178, 11–24 (2025).
Google Scholar
Ma, T. et al. Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma. Cell Death Dis. 16, 382 (2025).
Google Scholar
Hao, M.-W. et al. Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway. Med. Oncol. 42, 139 (2025).
Google Scholar
Ge, X. et al. Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibition. Preprint at https://doi.org/10.1101/2025.06.20.660715 (2025).
Hasan, A. M. W. et al. Quercetin promises anticancer activity through PI3K-AKT-mTOR pathway: a literature review. Pharm. Res. Nat. Prod. 7, 100206 (2025).
Maruyama, K. et al. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. NPJ Precis. Oncol. 9, 4 (2025).
Google Scholar
Porreca, V. et al. ERK1/2 signaling in intrahepatic cholangiocarcinoma: from preclinical advances to therapeutic strategies. Biology 14, 776 (2025).
Google Scholar
Tan, J. et al. Neobractatin and Trametinib SYNERGISTICALLY INDUCE APOPTOsis and Gasdermin E-DEPENDENT PYROPTOSIS IN PANCREATIC CANCER CElls. MedComm 6, e70250 (2025).
Google Scholar
Toyokuni, E. et al. Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer. Mol. Cancer Ther. 24, OF1–OF9 (2025).
Google Scholar
Bhatia, R. et al. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. NPJ Precis. Oncol. 9, 296 (2025).
Google Scholar
Zhang, S. et al. Transcytosis-triggering nanoparticles for overcoming stromal barriers and reversing immunosuppression in pancreatic cancer combinatorial therapy. Nano Lett. 25, 2949–2959 (2025).
Google Scholar
Girish, B. P. et al. Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Semin. Cancer Biol. 86, 1155–1162 (2022).
Google Scholar
Li, B., Zhang, Q., Castaneda, C. & Cook, S. Targeted therapies in pancreatic cancer: a new era of precision medicine. Biomedicines 12, 2175 (2024).
Google Scholar
Wang, X. et al. Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs. Mol. Cancer 24, 229 (2025).
Google Scholar
Hossain, M. A. Targeting the RAS upstream and downstream signaling pathway for cancer treatment. Eur. J. Pharmacol. 979, 176727 (2024).
Google Scholar
Christenson, E. S., Jaffee, E. & Azad, N. S. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 21, e135–e145 (2020).
Google Scholar
Umemoto, K. & Sunakawa, Y. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer. Crit. Rev. Oncol. Hematol. 166, 103465 (2021).
Google Scholar
Devi, S. & Chandrababu, R. Impact of Olaparib, Niraparib, Rucaparib therapies on newly diagnosed and relapsed ovarian cancer -systematic review and meta-analysis. Asian Pac. J. Cancer Prev. 26, 1931–1941 (2025).
Google Scholar
Wang, K. et al. Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells. Cell Res. 35, 362–380 (2025).
Google Scholar
Wei, D. et al. CAR-macrophage cell therapy: a new era of hope for pancreatic cancer. Clin. Cancer Res. 31, 4018–4031 (2025).
Google Scholar
Palencia-Campos, A. et al. Reprogramming tumor-associated macrophages with lipid nanosystems reduces PDAC tumor burden and liver metastasis. J. Nanobiotechnol. 22, 795 (2024).
Google Scholar
Zou, X. et al. ALDH1A3 promotes aggressive basal-like pancreatic cancer through an AP-1/RUNX2 enhancer network. Oncogene 44, 3774–3786 (2025).
Google Scholar
Chen, J. et al. Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe. Cell Death Dis. 16, 526 (2025).
Google Scholar
Fourtounis, J. et al. RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in CCNE1 amplified cancer cells. Cancer Res. 82, 5650–5650 (2022).
Google Scholar
